イサツキシマブ
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953105/.
↑ “Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab”. Cells 8 (12): 1522. (November 2019). doi:10.3390/cells8121522. PMC 6953105. PMID 31779273. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953105/.
↑ “A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma”. Blood 134 (2): 123–133. (July 2019). doi:10.1182/blood-2019-02-895193. PMC 6659612. PMID 30862646. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659612/.
↑ Martin, Thomas (2015年12月7日). “A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma”.